078340.KQ Daewoong Pharmaceutical Loading...

Loading chart...
Top Calls
Feed
Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
11:00
Jun 29
Lee Jae-kyu PB Deputy Manager, SK Securities 3PRO TV (삼프로TV)
Korean biotech catching up to US, overweight.
Korean biotech/pharma names have massively underperformed despite US biotech (XBI/NBI) trading at all-time highs. This decoupling is historically unusual and likely to narrow. Catalysts include the KOSDAQ 30th anniversary event starting with biotech sessions, continued foreign buying in KOSDAQ, and US-China tensions redirecting CDMO/ADC/double-antibody orders to Korean firms. Key stocks like Alteogen, DND Pharmatech, Hanall Biopharma, and Olix are showing improving technical patterns with foreign and institutional inflows. He advises overweighting biotech within a broader KOSDAQ allocation.
078340.KQ 1ST
HIGH

About 078340.KQ Analyst Coverage

Buzzberg tracks 078340.KQ (Daewoong Pharmaceutical) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (100%). 1 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: Lee Jae-kyu.